Clinical Trials
US Clinical Trial To Test Antiviral For Monkeypox Starts
In the United States, adults and kids with monkeypox infection are now being enrolled in a Phase 3 clinical trial assessing the antiviral tecovirimat, better known as TPOXX. The study's researchers hope to include more than 500 participants from...
Clinical Trials
Discoveries About Lumakra Lung Cancer Bolster The KRAS Fight
Amgen is in the lead in a carefully watched race among KRAS inhibitors after winning a lung cancer randomised study. Now, the California drugmaker is giving an early peek at the precise data that might set the benchmark for...
Clinical Trials
EU Officials Make New Work Plan To Speed-Up Clinical Study
The European Commission (EC), Heads of Medicine Agencies (HMA), and European Medicines Agency (EMA) have released the 2022–2026 workplan for the programme Accelerating Clinical Trials in the EU (ACT EU).
Building on the Clinical Trials Regulation (CTR) and Clinical Trials...
Drug Research
Prior To FDA Prurigo Nodularis Ruling, Dupixent Wins Again
Dupixent, the immunology favourite developed by Sanofi and Regeneron Pharmaceuticals, is still on the rise. It has received back-to-back approvals this year for the treatment of eosinophilic esophagitis and paediatric eczema, and now the IL-4/IL-13 inhibitor has achieved a...
IT & Data Management
FDA Experts Favor ALS Drug Amylyx, Shifting Former Stance
A group of Food and Drug Administration advisers has recently come out in favour of a carefully monitored ALS drug, increasing the likelihood that the agency will approve it in the coming weeks.
The expert group voted 7-2 in favour...
Drug Research
Long-Awaited Daxxify By Revance Will Compete With Botox
Revance Therapeutics may soon run into an identity problem with a product that is so eagerly awaited that some people mistakenly call it by the name of the firm. Daxxify, Revance's long-awaited Botox rival, has officially received FDA approval,...
Clinical Trials
Trodelvy Breast Cancer Drug Makes A Spectacular Comeback
After unimpressive evidence on tumour progression, many Gilead Sciences investors have stopped believing in Trodelvy in HR-positive, HER2-negative breast cancer. But now that the antibody-drug combination has unexpectedly returned, blockbuster dreams have been rekindled thanks to a life extension...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read